<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145751</url>
  </required_header>
  <id_info>
    <org_study_id>46937</org_study_id>
    <nct_id>NCT05145751</nct_id>
  </id_info>
  <brief_title>SARS CoV-2 Inflammatory Biomarkers</brief_title>
  <official_title>SARS CoV-2 Infection and Simple Inflammatory Biomarkers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Thessaly</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early research suggests that inflammation plays a key role in the development of SARS CoV-2&#xD;
      infection. The immune response to respiratory infection is characterized by an influx of&#xD;
      neutrophils to the lungs. We ought to investigate the association of simple biomarkers such&#xD;
      as NLR and PLR with the clinical outcome in SARS CoV-2 infection patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early research suggests that inflammation plays a key role in the development of SARS CoV-2&#xD;
      infection. The immune response to respiratory infection is characterized by an influx of&#xD;
      neutrophils to the lungs. Moreover, previous studies have demonstrated that a sustained&#xD;
      release of anti-inflammatory cytokines may lead to high levels of circulating neutrophils and&#xD;
      lymphocytes' apoptosis with subsequent lymphopenia and immune response imbalance. Therefore,&#xD;
      circulating biomarkers that represent inflammation and immune status could serve as potential&#xD;
      predictors for the prognosis of SARS CoV-2 patients. The neutrophil to lymphocyte ratio (NLR)&#xD;
      and platelet to lymphocyte ratio (PLR) are cheap and simply calculated biomarkers which have&#xD;
      been identified as markers of systemic inflammation, severity of the disease and prognosis in&#xD;
      several patient populations.&#xD;
&#xD;
      We ought to investigate the association of simple biomarkers such as NLR and PLR with the&#xD;
      clinical outcome in SARS CoV-2 infection patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome</measure>
    <time_frame>1 year</time_frame>
    <description>Outcome after COVID-19 infection</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>COVID-19 infection</arm_group_label>
    <description>Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simple inflammatory biomarkers measurement</intervention_name>
    <description>In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured</description>
    <arm_group_label>COVID-19 infection</arm_group_label>
    <other_name>Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with SARS CoV-2 infection who were treated by the Department of&#xD;
        Respiratory Medicine in the UHL will be done. The subjects will be followed from admission&#xD;
        to the hospital and up until discharge, transfer to the ICU or death&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2&#xD;
             infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients aged&lt;18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleni Arnaoutoglou, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Study Chair</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eleni Arnaoutoglou, M.D., Ph.D.</last_name>
    <phone>+306974301352</phone>
    <email>earnaout@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Ntalouka, M.D., Ph.D. M.Sc.</last_name>
    <phone>6973688099</phone>
    <email>maria.ntalouka@icloud.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univeristy of Thessaly</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Arnaoutoglou, MD, PhD</last_name>
      <phone>2413501370</phone>
      <email>earnaout@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Ntalouka, MD</last_name>
      <phone>+306973688099</phone>
      <email>maria.ntalouka@icloud.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Ntalouka, MD, PhD, Msc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleni Arnaoutoglou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Thessaly</investigator_affiliation>
    <investigator_full_name>Elena Arnaoutoglou</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

